EUPRAXIA PHARMACEUTICALS INC.
Business
Eupraxia Pharmaceuticals Inc. develops and commercializes novel local-delivery therapeutic candidates for inflammatory and musculoskeletal conditions. Its main products under development include EP-104IAR for osteoarthritis of the knee and EP-104GI for eosinophilic esophagitis, delivered via its DiffuSphere™ platform to provide sustained local corticosteroid exposure. The company organizes its activities around clinical development programs and regulatory affairs for its orthopedics and gastrointestinal therapeutic segments. Its programs are being advanced through clinical trials and regulatory interactions across Canada, the United States, Europe, Australia and Brazil.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-38.58M |
| Total assets | $86.15M |
| Total liabilities | $5.70M |
| Stockholders' equity | $82.04M |
| Operating cash flow | $-28.55M |